chr8-19955874-G-A
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM5PP3_StrongPP5_Very_Strong
The NM_000237.3(LPL):c.809G>A(p.Arg270His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,614,004 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R270C) has been classified as Pathogenic.
Frequency
Consequence
NM_000237.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LPL | NM_000237.3 | c.809G>A | p.Arg270His | missense_variant | 6/10 | ENST00000650287.1 | NP_000228.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LPL | ENST00000650287.1 | c.809G>A | p.Arg270His | missense_variant | 6/10 | NM_000237.3 | ENSP00000497642 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152132Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251284Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135802
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461872Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 10AN XY: 727236
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152132Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74300
ClinVar
Submissions by phenotype
Hyperlipoproteinemia, type I Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | DASA | Jan 05, 2022 | The c.809G>A;p.(Arg270His) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 1530; OMIM: 609708.0011; PMID: 23484243; 25966443; 7906986) - PS4. Well-established in vitro or in vivo functional studies support a damaging effect on the gene or gene product (PMID: 1752947) - PS3_supporting. The variant is located in a mutational hot spot and/or critical and well-established functional domain (Lipase) - PM1. The variant is present at low allele frequencies population databases (rs118204062– gnomAD 0.0001315%; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2_supporting. The p.(Arg270His) was detected in trans with a pathogenic variant (PMID: 25966443) - PM3. Pathogenic missense variant in this residue have been reported (ClinVar ID: 1548; PMID: 29153744) - PM5. The variant co-segregated with disease in multiple affected family members (PMID: 25966443; 23484243) - PP1_strong. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 06, 2022 | Variant summary: LPL c.809G>A (p.Arg270His) results in a non-conservative amino acid change located in the Lipase domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251284 control chromosomes. c.809G>A has been reported in the literature in multiple individuals affected with Familial Lipoprotein Lipase Deficiency in the homozygous and compound heterozygous state (Gotoda_1991, Ishimura-Oka_1992, Suzuki_2016). These data indicate that the variant is very likely to be associated with disease. Expression studies have shown the variant to have no detectable enzymatic activity (Gotoda_1991, Ishimura-Oka_1992). Other variants affecting the same codon have been reported in association with Lipoprotein lipase deficiency and Hypertriglyceridaemia (R270C, R270G, R270L; HGMD). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Four labs classified the variant as pathogenic while one classified as VUS. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1994 | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 24, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg270 amino acid residue in LPL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7906986, 25966443, 29153744). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects LPL function (PMID: 1752947). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LPL protein function. ClinVar contains an entry for this variant (Variation ID: 1530). This variant is also known as p.Arg243His. This missense change has been observed in individuals with clinical features of lipoprotein lipase deficiency (PMID: 7906986, 23484243, 25966443). This variant is present in population databases (rs118204062, gnomAD 0.003%). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 270 of the LPL protein (p.Arg270His). - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 31, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate a decreased levels of LPL mass in media and non-detectable enzymatic activity in transfected cells (Gotoda et al., 1991).; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as p.(R243H); This variant is associated with the following publications: (PMID: 27055971, 7906986, 23484243, 1752947, 27153815, 1702428, 1619366, 32041611, 33303402, 23337350) - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Hyperlipidemia, familial combined, LPL related Pathogenic:1
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Aug 05, 2024 | The p.Arg270His variant in LPL has been reported in 6 individuals (Dutch, Italian, Japanese, and Chinese) with familial combined hyperlipidemia (PMID: 22239554, 29748148, 25966443, 1752947, 7906986), and has been identified in 0.003% (1/30614) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs118204062). This variant has also been reported in ClinVar as pathogenic (Variation ID: 1530). In vitro functional studies provide some evidence that the p.Arg270His variant may impact protein function (PMID: 1752947). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS3_supporting, PP3, PM2 (Richards 2015). - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 21, 2022 | The p.R270H pathogenic mutation (also known as c.809G>A), located in coding exon 6 of the LPL gene, results from a G to A substitution at nucleotide position 809. The arginine at codon 270 is replaced by histidine, an amino acid with highly similar properties. This alteration has been detected in homozygous and compound heterozygous patients with severe hypertriglyceridemia and chylomicronemia (Gotoda T et al. J Clin Invest, 1991 12;88:1856-64; Ma Y et al. Hum Mutat, 1994;3:52-8; Behar DM et al. Isr Med Assoc J, 2013 Jan;15:53-4). In vitro studies have found this mutation impairs LPL protein function (Gotoda T et al. J Clin Invest, 1991 12;88:1856-64). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at